With bunk blood tests and medical equipment, possible federal sanctions, a criminal probe, voided patient reports, and possible class action lawsuits, Theranos has taken quite the hit.

On Wednesday, Forbes put dollar values to that hit. The business magazine reported that the company’s valuation—based on “a dozen venture capitalists, analysts and industry experts”—has been downgraded from its $9 billion estimate 2014 to just $800 million now. And because Forbes’ valuation of Theranos CEO and founder, Elizabeth Holmes, was based solely on her 50 percent stake in the company, their estimate of her net worth dropped from $4.5 billion to “nothing.”

In 2015, Forbes ranked Holmes the number one self-made woman in America.

In a statement, Theranos spokesperson Brooke Buchanan fired back at the new valuations, saying: “As a privately held company, we declined to share confidential information with Forbes. As a result, the article was based exclusively on speculation and press reports.”

Forbes gave three reasons that Theranos has lost value: too many questions about its work remain; it’s have failed to deliver data on its tests and machines; and it’s unlikely to outdo its competitors.

“[G]iven the difficulties at Theranos,” Forbes concluded that “Holmes falls off the list of America’s Richest Self-Made Women and off all of FORBES’ other wealth lists.”